AB
BHVN

Amalgamated Bank’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Amalgamated Bank’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,437
Closed -$1.43M – 3010
2022
Q3 		$1.43M Buy
9,437
+245
+3% +$36.3K 0.01% 971
2022
Q2 		$1.34M Buy
9,192
+863
+10% +$110K 0.01% 1031
2022
Q1 		$988K Sell
8,329
-624
-7% -$77.8K 0.01% 1204
2021
Q4 		$1.23M Sell
8,953
-88
-1% -$11.2K 0.01% 1143
2021
Q3 		$1.26M Sell
9,041
-306
-3% -$38.2K 0.01% 1136
2021
Q2 		$907K Buy
9,347
+2,497
+36% +$203K 0.01% 1339
2021
Q1 		$468K Sell
6,850
-668
-9% -$54K 0.02% 1022
2020
Q4 		$644K Buy
7,518
+40
+0.5% +$3.39K 0.02% 818
2020
Q3 		$486K Sell
7,478
-71
-0.9% -$4.65K 0.02% 850
2020
Q2 		$552K Buy
7,549
+182
+2% +$9.69K 0.03% 780
2020
Q1 		$251K Buy
7,367
+198
+3% +$9.05K 0.01% 1238
2019
Q4 		$390K Buy
7,169
+615
+9% +$30.5K 0.01% 1253
2019
Q3 		$273K Buy
6,554
+588
+10% +$24.8K 0.01% 1369
2019
Q2 		$261K Buy
5,966
+1,252
+27% +$70.6K 0.01% 1436
2019
Q1 		$243K Buy
+4,714
New +$204K 0.01% 1397

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Amalgamated Bank's BHVN Position: Q4 2022 in Review

Amalgamated Bank sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 9,437 shares — an estimated $1.43M sold.

Amalgamated Bank first reported a position in BHVN in Q1 2019 and held it in 15 quarters. The position peaked at $1.43M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Amalgamated Bank reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Amalgamated Bank sold 9,437 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.43M.
  • Amalgamated Bank first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 15 quarters.
  • Amalgamated Bank's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.43M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Amalgamated Bank's 13F filing for Q4 2022, filed 10 Feb 2023.